

Remarks/Arguments

Applicants have amended the instant application to cancel claims 1-24, 29 and 32 – 35 and add new claims 37 – 45. Claims 25 – 28, 30-31 and 36 were previously cancelled. Accordingly, claims 37-45 are the claims now pending in the application. Claim 37 is directed to the specific compound 5-(3-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid (S)-piperidin-3-ylamide and pharmaceutically acceptable salts thereof support for which can be found, e.g., on pages 63-67 and page 19, lines 25-26 of the specification. Claim 38 is directed to a method of limiting cell-proliferation, claim 39 is directed to treating cancer, claim 40 is directed to the prophylaxis treatment of cancer, and claims 40- 44 are directed to further methods of treating cancer all comprising administering the compound of claim 37. Claim 45 is directed to pharmaceutical compositions comprising the compound of claim 37. Support for claims 38-40 can be found, e.g., in the originally presented claims.

It is respectfully submitted no new matter has been added by the instant amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101367-1P US.

Respectfully submitted,
/Carol A. Loeschorn/

Name: Carol A. Loeschorn
Dated: 23 October 2008
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451